Further, Kenny et al. reported that in vitro and in vivo treatments with a uPA receptor (uPAR) antibody inhibited ovarian cancer cell invasion, migration, and adhesion by inhibiting α5-integrin and decreasing the expression of urokinase, uPAR, β3-integrin, and fibroblast growth factor receptor-1 [195]. This evidence concerns the gene PLAUR and ovarian cancer.